Zongertinib, a human epidermal growth factor receptor 2 targeted tyrosine kinase inhibitor, elicited durable responses in patients with advanced, previously treated non-small cell lung cancer that harbored a HER2 mutation, according to results from the phase IA/IB Beamion LUNG-1 trial.Â
The University of California Lung Cancer Consortium and AstraZeneca announced a five-year partnership to expand the Healthy Lungs California initiative, which is aimed at increasing early lung cancer detection and reducing deaths from the disease.Â
A team of researchers from the Keck School of Medicine of USC has developed an advanced tool for analyzing chimeric antigen receptor T cells, including how they evolve during manufacturing and which ones are most effective at killing cancer.Â
Researchers at the University of California San Diego School of Medicine have found that individuals with colon cancer and a documented history of high cannabis use were more than 20 times more likely to die within five years of diagnosis compared to those without such a history.
An artificial intelligence-based model developed by UT Southwestern Medical Center researchers can accurately predict which kidney cancer patients will benefit from anti-angiogenic therapy, a class of treatments that’s only effective in some patients.Â
Avenda Health has announced study results showing that its cancer mapping tool, Unfold AI, predicts cancer spread more accurately than MRI.
The DESTINY-Breast09 phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current first-line standard of care.
Cleveland Clinic Abu Dhabi, in collaboration with experts from Cleveland Clinic in the U.S., performed the world’s first remotely conducted transcontinental robotic-assisted focal therapy for prostate cancer.Â
Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and Memorial Sloan Kettering Cancer Center in New York have found a link between two genetic mutations in a subtype of acute myeloid leukemia, which could lead to new ways to treat the disease.
Researchers at Baylor College of Medicine, Texas Children’s Hospital, the Hospital for Sick Children in Toronto and collaborating institutions revealed in Nature Cell Biology a strategy that helps medulloblastoma, the most prevalent malignant brain tumor in children, spread and grow on the leptomeninges, the membranes surrounding the brain and spinal cord.
